GLP-1 weight-loss drugs such as Ozempic and Wegovy are driving down grocery spending, according to a new study from Cornell’s ...

Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...

While West Virginia's employee health insurance program covers drugs like Ozempic for people with type 2 diabetes, officials ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

According to the study, participants taking Zepbound lost an average of 20.2% of their starting weight after 72 weeks, ...

For a long time, dieting and exercise were the only realistic options for many people who wanted to lose weight, but recent ...

According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound will overtake competitors.

My weight concerns mainly injure my considerable vanity, and I’m not about to outsource my self-esteem issue to Big Pharma if ...

Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.

Weight Loss Industry Booms as Obesity Rates Rise and GLP-1 drugs are seen as a revolutionary innovation for weight loss.